Genetic Technologies Stock Price, News & Analysis (NASDAQ:GENE)

$0.92 0.00 (0.00 %)
(As of 12/12/2017 05:24 AM ET)
Previous Close$0.92
Today's Range$0.89 - $0.95
52-Week Range$0.70 - $1.38
Volume72,900 shs
Average Volume173,828 shs
Market Capitalization$14.94 million
P/E RatioN/A
Dividend YieldN/A
Beta2.66

About Genetic Technologies (NASDAQ:GENE)

Genetic Technologies Limited is a molecular diagnostics company. The Company is engaged in the provision of molecular risk assessment for cancer. The Company offers predictive testing and assessment tools for physicians to manage women's health. The Company's lead product, BREVAGenplus, is a clinically validated risk assessment test for non-hereditary breast cancer. The Company markets BREVAGenplus to healthcare professionals in breast healthcare and imaging centers, as well as to obstetricians/gynecologists (OBGYNs) and breast cancer risk assessment specialists, such as breast surgeons. The Company operates in Australia, the United States and Switzerland. The Company's subsidiaries include Genetic Technologies Corporation Pty. Ltd. and Phenogen Sciences Inc. Genetic Technologies Corporation Pty. Ltd. is engaged in genetic testing. The Company has launched the BREVAGen test across the United States through Phenogen Sciences Inc.

Receive GENE News and Ratings via Email

Sign-up to receive the latest news and ratings for GENE and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:GENE
CUSIPN/A
Phone61-3-8412-7000

Debt

Debt-to-Equity RatioN/A
Current Ratio7.96%
Quick Ratio7.96%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$390,000.00
Price / Sales38.31
Cash FlowN/A
Price / CashN/A
Book Value$0.49 per share
Price / Book1.88

Profitability

Trailing EPSN/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees25
Outstanding Shares16,240,000

Genetic Technologies (NASDAQ:GENE) Frequently Asked Questions

What is Genetic Technologies' stock symbol?

Genetic Technologies trades on the NASDAQ under the ticker symbol "GENE."

Who are some of Genetic Technologies' key competitors?

Who are Genetic Technologies' key executives?

Genetic Technologies' management team includes the folowing people:

  • Eutillio Buccilli, Chief Executive Officer, Executive Director
  • Kevin Fischer, Chief Financial Officer, Company Secretary
  • Mark Ostrowski, President of Phenogen Sciences Inc (Age 50)
  • Richard Allman Ph.D, Scientific Director (Age 53)
  • M. Luisa Ashdown, Director of Global Licensing and Intellectual Property (Age 57)
  • Susan J. Gross M.D., Senior Medical Director
  • Diana Newport, Quality and Business Operations Director (Age 56)
  • Malcolm Roy Brandon Ph.D., Non-Executive Chairman of the Board (Age 66)
  • Grahame James Leonard, Director
  • Paul Alexander Kasian, Non-Executive Director

How do I buy Genetic Technologies stock?

Shares of Genetic Technologies can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Genetic Technologies' stock price today?

One share of Genetic Technologies stock can currently be purchased for approximately $0.92.

How big of a company is Genetic Technologies?

Genetic Technologies has a market capitalization of $14.94 million and generates $390,000.00 in revenue each year. Genetic Technologies employs 25 workers across the globe.

How can I contact Genetic Technologies?

Genetic Technologies' mailing address is 60-66 HANOVER STREET, FITZROY C3, 3065. The biotechnology company can be reached via phone at 61-3-8412-7000 or via email at [email protected]


MarketBeat Community Rating for Genetic Technologies (GENE)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  39 (Vote Outperform)
Underperform Votes:  45 (Vote Underperform)
Total Votes:  84
MarketBeat's community ratings are surveys of what our community members think about Genetic Technologies and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Genetic Technologies (NASDAQ:GENE) Analyst Ratings History


No equities research coverage for this company has been tracked by MarketBeat

Earnings

Earnings History for Genetic Technologies (NASDAQ:GENE)


No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Genetic Technologies (NASDAQ:GENE) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Genetic Technologies (NASDAQ:GENE)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Genetic Technologies (NASDAQ GENE)

No insider trades for this company have been tracked by MarketBeat.com

Headlines

Genetic Technologies (NASDAQ GENE) News Headlines

Source:
DateHeadline
Global Recombinant DNA (rDNA) Technology Market Report, Size, Share, Analysis 2017 and Forecast to 2023Global Recombinant DNA (rDNA) Technology Market Report, Size, Share, Analysis 2017 and Forecast to 2023
www.marketwatch.com - October 31 at 8:11 PM
Genetic Technologies Limited: Quarterly Activities Report and Appendix 4C of the ASX Listing RulesGenetic Technologies Limited: Quarterly Activities Report and Appendix 4C of the ASX Listing Rules
www.nasdaq.com - October 30 at 7:52 PM
Genetic Technologies Limited: Quarterly Activities Report and Appendix 4C of the ASX Listing Rules for the quarter ended 30 September 2017Genetic Technologies Limited: Quarterly Activities Report and Appendix 4C of the ASX Listing Rules for the quarter ended 30 September 2017
finance.yahoo.com - October 30 at 7:52 PM
Antibody Drugs: Technologies and Global MarketsAntibody Drugs: Technologies and Global Markets
www.bizjournals.com - October 10 at 4:43 PM
Todays Research Reports on Stocks to Watch: Tetraphase Pharmaceuticals and Genetic TechnologiesToday's Research Reports on Stocks to Watch: Tetraphase Pharmaceuticals and Genetic Technologies
finance.yahoo.com - October 5 at 8:34 AM
A Moral Duty To AbortA Moral Duty To Abort
www.huffingtonpost.com - September 23 at 5:46 AM
Genetic Technologies Transitions to Online Commercial Platform for BREVAGenplus®Genetic Technologies Transitions to Online Commercial Platform for BREVAGenplus®
finance.yahoo.com - September 22 at 2:35 PM
Global Industrial Enzyme Market Growth Estimated At CAGR Of 5.8% For The Forecast Period 2016-2023: Occams Business Research & Consulting Pvt. Ltd.Global Industrial Enzyme Market Growth Estimated At CAGR Of 5.8% For The Forecast Period 2016-2023: Occams Business Research & Consulting Pvt. Ltd.
www.thestreet.com - September 13 at 5:51 AM
Genetic Technologies Ltd. :GENE-US: Earnings Analysis: For the six months ended June 30, 2017 : September 1, 2017Genetic Technologies Ltd. :GENE-US: Earnings Analysis: For the six months ended June 30, 2017 : September 1, 2017
finance.yahoo.com - September 1 at 7:21 PM
Benitec Biopharmas (BNIKF) CEO Greg West on Q2 2017 Results - Earnings Call TranscriptBenitec Biopharma's (BNIKF) CEO Greg West on Q2 2017 Results - Earnings Call Transcript
seekingalpha.com - August 31 at 3:54 AM
Genetic Technologies Announces Comprehensive Review of Strategic AlternativesGenetic Technologies Announces Comprehensive Review of Strategic Alternatives
finance.yahoo.com - August 25 at 5:47 AM
Silicon Valley Startup Grail Sees Hope for Cancer Blood TestSilicon Valley Startup Grail Sees Hope for Cancer Blood Test
www.bloomberg.com - August 9 at 7:09 PM
Inside the Secret World of Global Food SpiesInside the Secret World of Global Food Spies
www.bloomberg.com - August 7 at 4:17 PM
Research Published in Molecular Therapy Identifies Optimal Gene-based Therapeutic Construct for X-Linked Retinitis PigmentosaResearch Published in Molecular Therapy Identifies Optimal Gene-based Therapeutic Construct for X-Linked Retinitis Pigmentosa
globenewswire.com - August 7 at 4:17 PM
DVAX Plunges On Delay In Approval, FDA Nod For ABBVs HCV Drug, ABIO On RadarDVAX Plunges On Delay In Approval, FDA Nod For ABBV's HCV Drug, ABIO On Radar
www.rttnews.com - August 5 at 12:18 AM
Biotechnology: the US-China dispute over genetic dataBiotechnology: the US-China dispute over genetic data
www.ft.com - August 1 at 7:34 PM
Novel Genetic Test Could Help Combat the Opioid Epidemic by Identifying Patients at Risk of AddictionNovel Genetic Test Could Help Combat the Opioid Epidemic by Identifying Patients at Risk of Addiction
www.bizjournals.com - August 1 at 7:34 PM
Genetic Technologies Launches Breast Cancer Awareness Month Promotion for BREVAGenplus(R)Genetic Technologies Launches Breast Cancer Awareness Month Promotion for BREVAGenplus(R)
finance.yahoo.com - August 1 at 7:34 PM
Genetic Technologies Limited: Quarterly Activities Report and Appendix 4C of the ASX Listing Rules for the quarter ended 30 June 2017Genetic Technologies Limited: Quarterly Activities Report and Appendix 4C of the ASX Listing Rules for the quarter ended 30 June 2017
finance.yahoo.com - July 28 at 12:36 AM
Preimplantation Genetic Testing Market by Type, Technology, Products ...Preimplantation Genetic Testing Market by Type, Technology, Products ...
www.prnewswire.com - July 23 at 12:29 AM
Genetic Technologies Receives Nasdaq Deficiency NoticeGenetic Technologies Receives Nasdaq Deficiency Notice
finance.yahoo.com - July 22 at 12:09 AM
Eloxx Pharmaceuticals Receives a US$6 Million Investment from KIP and DCS to Advance a Novel Disease-Modifying Therapy Targeting Genetic Diseases Including Cystic FibrosisEloxx Pharmaceuticals Receives a US$6 Million Investment from KIP and DCS to Advance a Novel Disease-Modifying Therapy Targeting Genetic Diseases Including Cystic Fibrosis
www.businesswire.com - June 26 at 6:59 PM
Global Genetic Testing IndustryGlobal Genetic Testing Industry
www.bizjournals.com - June 23 at 3:27 PM
Canopy Biosciences Announces Distribution Agreement with Cosmo Bio for Japan Life Science MarketCanopy Biosciences Announces Distribution Agreement with Cosmo Bio for Japan Life Science Market
www.bizjournals.com - June 22 at 9:31 AM
Genomic Vision Inks Chinese Distribution Deal with APG Bio LtdGenomic Vision Inks Chinese Distribution Deal with APG Bio Ltd
www.businesswire.com - June 20 at 2:21 AM
Global 2017 Genetic Testing Strategic Business Report - Research and MarketsGlobal 2017 Genetic Testing Strategic Business Report - Research and Markets
www.finanznachrichten.de - June 19 at 4:18 PM
Sevion Therapeutics Inc. and Eloxx Pharmaceuticals Ltd Announce the Entering into of an Acquisition TransactionSevion Therapeutics Inc. and Eloxx Pharmaceuticals Ltd Announce the Entering into of an Acquisition Transaction
www.businesswire.com - June 2 at 11:44 PM
In ‘Enormous Success,’ Scientists Tie 52 Genes to Human IntelligenceIn ‘Enormous Success,’ Scientists Tie 52 Genes to Human Intelligence
www.nytimes.com - May 22 at 4:58 PM
NewStem Introduces Novel Technology for Predicting Resistance to ChemotherapiesNewStem Introduces Novel Technology for Predicting Resistance to Chemotherapies
www.streetinsider.com - May 22 at 4:58 PM
5 Things You Need To Know Before Taking an At-Home Genetic Test5 Things You Need To Know Before Taking an At-Home Genetic Test
www.nbcnews.com - May 16 at 5:20 PM
Applied Genetic Technologies (AGTC) CEO Sue Washer on Q3 2017 Results - Earnings Call TranscriptApplied Genetic Technologies' (AGTC) CEO Sue Washer on Q3 2017 Results - Earnings Call Transcript
seekingalpha.com - May 10 at 10:56 PM
Applied Genetic Technologies (AGTC) & Collaborators Announce New Data on the Natural History of X-Linked Retinoschisis (XLRS)Applied Genetic Technologies (AGTC) & Collaborators Announce New Data on the Natural History of X-Linked Retinoschisis (XLRS)
www.streetinsider.com - May 9 at 11:38 AM
Kaiima and Becks Announce Collaboration Using the EP™ Technology Platform to Improve Corn Hybrid YieldKaiima and Beck's Announce Collaboration Using the EP™ Technology Platform to Improve Corn Hybrid Yield
www.prnewswire.com - May 8 at 5:10 PM
Myriad Genetics Reports Fiscal Third-Quarter 2017 Financial ResultsMyriad Genetics Reports Fiscal Third-Quarter 2017 Financial Results
globenewswire.com - May 2 at 7:16 PM
Agios and Aurigene Enter into Exclusive License Agreement for Novel Small Molecules for Cancer Metabolism TargetAgios and Aurigene Enter into Exclusive License Agreement for Novel Small Molecules for Cancer Metabolism Target
globenewswire.com - April 27 at 8:03 AM
Congenica and Edico Genome Partner to Speed Analysis from DNA to Diagnosis for Inherited DiseasesCongenica and Edico Genome Partner to Speed Analysis from 'DNA to Diagnosis' for Inherited Diseases
www.prnewswire.com - April 20 at 5:29 PM
We Might Soon Resurrect Extinct Species. Is It Worth the Cost?We Might Soon Resurrect Extinct Species. Is It Worth the Cost?
www.nytimes.com - March 21 at 8:52 AM
What Happens When Consumers Begin to Engage With Their Own Health?What Happens When Consumers Begin to Engage With Their Own Health?
www.fool.com - March 21 at 8:52 AM
Could GM moth larvae reduce animal testing?Could GM moth larvae reduce animal testing?
www.reuters.com - March 17 at 5:41 PM
Preimplantation Genetic Testing (PGT) Market Size & Forecast By Type, By Application, And Segment Forecasts To 2024Preimplantation Genetic Testing (PGT) Market Size & Forecast By Type, By Application, And Segment Forecasts To 2024
www.prnewswire.com - March 14 at 12:26 PM
BRIEF-Betta Pharmaceuticals signs strategic cooperation agreement for precision medical businessBRIEF-Betta Pharmaceuticals signs strategic cooperation agreement for precision medical business
www.reuters.com - February 28 at 8:49 AM
Elbit Imaging Ltd. Announces That Gamida Cells Has Made First Patient Transplanted in Phase 3 Registration Study of Nicord for Blood CancersElbit Imaging Ltd. Announces That Gamida Cell's Has Made First Patient Transplanted in Phase 3 Registration Study of Nicord for Blood Cancers
www.baystreet.ca - February 28 at 8:49 AM
A US panel has endorsed limited genetic modification of humans — heres what that meansA US panel has endorsed limited genetic modification of humans — here's what that means
www.businessinsider.com - February 20 at 11:06 AM
Seattle Genetics (SGEN) Loss Wider than Expected in Q4, Revenues Miss - NasdaqSeattle Genetics (SGEN) Loss Wider than Expected in Q4, Revenues Miss - Nasdaq
www.nasdaq.com - February 11 at 4:04 AM
AGTC Selected as Top Company in the University of Floridas 2017 ... - NasdaqAGTC Selected as Top Company in the University of Florida's 2017 ... - Nasdaq
www.nasdaq.com - February 11 at 4:04 AM
AGTC Selected as Top Company in the University of Florida’s 2017 Gator100AGTC Selected as Top Company in the University of Florida’s 2017 Gator100
globenewswire.com - February 10 at 6:02 PM
AGTC and Bionic Sight Announce Strategic Collaboration to Develop an Optogenetic Therapy and Device for Visual Deficits and BlindnessAGTC and Bionic Sight Announce Strategic Collaboration to Develop an Optogenetic Therapy and Device for Visual Deficits and Blindness
globenewswire.com - January 24 at 6:05 PM
Silicon Valley Biotech Showcase Forecasts The Future Of Pain Treatment - ForbesSilicon Valley Biotech Showcase Forecasts The Future Of Pain Treatment - Forbes
www.forbes.com - January 23 at 5:44 PM
Biogens Multiple Sclerosis Franchise to Drive Growth in 2017 - NasdaqBiogen's Multiple Sclerosis Franchise to Drive Growth in 2017 - Nasdaq
www.nasdaq.com - January 18 at 1:21 AM
Form SC 13G/A GENETIC TECHNOLOGIES Filed by: SABBY ... - StreetInsider.comForm SC 13G/A GENETIC TECHNOLOGIES Filed by: SABBY ... - StreetInsider.com
www.streetinsider.com - January 13 at 3:56 AM

SEC Filings

Genetic Technologies (NASDAQ:GENE) SEC Filings

DateFilerForm TypeView
12/01/2017
8:39 AM
Genetic Technologies (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
View Filing

Social Media

Financials

Genetic Technologies (NASDAQ:GENE) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Genetic Technologies (NASDAQ GENE) Stock Chart for Tuesday, December, 12, 2017

Loading chart…

This page was last updated on 12/12/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.